R. Velmurugan1, P. Manoj Kumar2, Keerthi G.S. Nair2, *
Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai 600117, India
Department of Pharmaceutics, The Dale View College of Pharmacy and Research Centre, Punalal, Poovachal, Trivandrum, Kerala 695575, India
Received 17 March 2021, Accepted 5 July 2021, Available Online 16 July 2021.
- COVID-19; remdesivir; hepatotoxicity; nanoparticle; target delivery; ashwagandha; improved clinical outcome
Remdesivir is a broad spectrum antiviral agent meant to inhibit viral RNA polymerases against members of several virus families, including filoviruses. Although reported for significant clinical improvements in COVID-19, a detailed observation of the connection with the drawbacks of remdesivir therapy was poor pulmonary distribution and hepatotoxicity (transaminase elevation) was recorded that resulted in discontinuation of remdesivir therapy. Nanodrug delivery facilitates a large drug payload to the targeted site improving the efficacy. With the lesser dose administered, could be expected for minimized adverse events. Additional payload of ashwagandha will protect the liver from the damages caused if any. Remdesivir in nanoformulation may be a safe and an effective therapeutic agent for COVID 19 when co-adminstered with ashwagandha.
- © 2021 The Authors. Published by Atlantis Press B.V.
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).